Who are AZD7009, no generic name available's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd7009-no-generic-name-available.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AZD7009, no generic name available — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD7009, no generic name available (AZD7009, no generic name available) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K delta and PI3K gamma inhibitor. Area: Immunology.

phase 2 PI3K delta and PI3K gamma inhibitor PI3K delta and PI3K gamma Immunology Small molecule Live · refreshed every 30 min

Target snapshot

AZD7009, no generic name available (AZD7009, no generic name available) — AstraZeneca. AZD7009 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZD7009, no generic name available TARGET	AZD7009, no generic name available	AstraZeneca	phase 2	PI3K delta and PI3K gamma inhibitor	PI3K delta and PI3K gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K delta and PI3K gamma inhibitor class)

AstraZeneca · 6 drugs in this class
Aclaris Therapeutics, Inc. · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Southern Europe New Drug Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD7009, no generic name available — Competitive Intelligence Brief. https://druglandscape.com/ci/azd7009-no-generic-name-available. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab